June 26, 2024 02:51 PM EDT
Deals
Pharma

Ha­le­on to sell nico­tine re­place­ment ther­a­py busi­ness to Dr. Red­dy’s for $630M

Lia DeGroot

Ha­le­on has agreed to sell its ex-US nico­tine re­place­ment ther­a­py busi­ness to Dr. Red­dy’s for a to­tal of £500 mil­lion, or about $630 mil­lion, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

A service from the Financial Times